Description
SS-31 10mg is the Core Research catalogue item for 10mg nominal of SS-31, a mitochondrial-targeted tetrapeptide also called elamipretide in research literature. It is supplied as one lyophilised research-peptide vial for in-vitro laboratory research only; not for human or veterinary use. The material and model-level science below must be distinguished from product-specific analytical results and finished-format performance.
What you receive and what needs verifying
| Field | What this product listing establishes |
|---|---|
| Exact catalogue item | SS-31 10mg |
| Labelled amount | 10mg nominal; not an independently measured quantitative assay |
| Presentation | one lyophilised research-peptide vial |
| Research identity | SS-31, a mitochondrial-targeted tetrapeptide also called elamipretide in research literature |
| Supply boundary | In-vitro laboratory research only; no personal or veterinary use |
| Current price and stock | Shown by the live WooCommerce purchase panel; not fixed in this description |
The vial is the catalogue item: no cartridge, dispensing pen, buffer or administration accessory is stated as part of this purchase. The labelled milligram value is an amount per vial, not a prepared-solution concentration.
Before ordering, check the material identity, the form on the actual label and any information your assay needs from the applicable certificate. An unrelated paper, a general PubChem record or another catalogue format cannot establish a batch value for this particular item.
Which compound or format is the right laboratory item?
Different from metabolic substrates. SS-31 is a mitochondria-directed tetrapeptide studied for membrane interactions. NAD+ is an oxidised redox cofactor, and MOTS-c is a mitochondrially encoded signalling peptide; their identities and assay endpoints are not equivalent.
Related formats and research alternatives
Compare SS-31 with 5-Amino-1MQ and the broader Metabolic & NAD+ Research catalogue by their distinct target biology. SS-31 focuses on cardiolipin and mitochondrial protein interactions, whereas NNMT inhibitors perturb methyl-transfer metabolism.
Scientific research: mechanisms, measured results and limits
The following is a selected, model-specific evidence summary, not a systematic review, treatment recommendation or release test of this product. Read the study species, methods and measured endpoints beside each finding before transferring an interpretation to a different assay.
Cardiolipin and the inner mitochondrial membrane
SS-31 is a short, alternating aromatic–cationic tetrapeptide studied for interactions with cardiolipin, a negatively charged phospholipid enriched in the inner mitochondrial membrane. Cardiolipin helps organise cristae structure and protein complexes involved in electron transport. Birk and colleagues reported cardiolipin-associated SS-31 findings together with changes in cytochrome-c peroxidase activity and mitochondrial recovery after renal ischaemia in an experimental model. These are mechanistic and animal data, not a universal effect in every tissue or a property demonstrated for this 10mg vial. 1
Cytochrome c, cristae and ATP are different endpoints
Cytochrome c participates in electron transport and can exhibit peroxidase activity in a different lipid-associated context. The 2013 research connected SS-31–cardiolipin interaction with measures of cytochrome-c behaviour, preservation of membrane organisation and ATP recovery after experimentally induced ischaemia. A biochemical interaction, a microscopy observation and a tissue-injury outcome differ in what they prove; a favourable observation in one does not establish a generic antioxidant or tissue-repair guarantee. 1
Proteomics suggests more than a single protein target
A 2020 chemical-cross-linking and mass-spectrometry study mapped multiple mitochondrial proteins in proximity to SS-31. Reported interactors included proteins involved in oxidative phosphorylation and 2-oxoglutarate metabolism; many binding regions were near known cardiolipin-contact surfaces. This supports a more complex interaction landscape than a single universal receptor claim. Cross-linking detects experimentally accessible molecular proximity, and its identified proteins should not automatically be described as direct functional targets in every biological system. 2
Controlled human results have to be separated from extensions
In a randomised, double-blind, placebo-controlled crossover trial in Barth syndrome, the predefined primary endpoints—six-minute walking performance and a fatigue/symptom assessment—were not met during the controlled phase. Later open-label extensions reported changes in several functional and cardiac measures. These are meaningful research observations, but an uncontrolled extension cannot establish the same causal conclusion as the blinded comparison. Neither trial used this supplier research vial or validates its finished-material specification. 3,4
SS-31 is not interchangeable with a clinical formulation
The names SS-31, elamipretide and related development designations can refer to the studied tetrapeptide, but medicinal research also involves a particular chemical form, manufactured specification, formulation and quality system. An observed result for a named clinical product does not prove pharmaceutical equivalence, sterile suitability, stable solution life or an administration route for laboratory material sold under the same peptide name. This product remains a research item, not a substitute for a clinical preparation. 3
How to interpret the evidence for this product
| Research context | Reported or relevant endpoint | Interpretation limit |
|---|---|---|
| Isolated mitochondria / renal models | Cardiolipin interaction, cytochrome-c response, cristae and ATP | Model-specific mitochondrial effects |
| Cross-linking mass spectrometry | Mitochondrial protein proximity | Proximity is not universal direct-target proof |
| Barth-syndrome clinical programme | Controlled functional endpoints versus later open-label observations | The primary controlled endpoints were not met |
Batch documentation before purchase
Core Research allows a pre-purchase batch-documentation enquiry. Use Batch Documentation or email info@core-research.net with the exact product name and presentation. An order or container lot number is not needed to ask the question before purchase; to match a supplied item after delivery, retain its lot identifier and order reference. The published delivery policy says a certificate is issued with a consignment where one exists for the supplied lot; that is not a promise of a current certificate for every item.
Ask whether documentation applies to the lot proposed for supply and identifies the tested chemical form, sample description, method, result, reporting basis, testing issuer and relevant dates. The difference between chromatographic peak-area purity, identity/mass and quantitative vial content matters.
For interpretation, use guide to reading a CoA, HPLC testing guide and mass-spectrometry guide. A theoretical molecular formula is not a batch-assay result, and a product label does not certify sterility.
For SS-31 10mg, confirm sequence, terminal modification, exact salt/solid form and the expected analytical ion assignment. An experimental elamipretide formulation or medicinal product specification is not evidence that this vial meets those requirements.
Storage, receiving and laboratory quality control
A lyophilised vial is different from a liquid solution. Check the lot-specific storage document rather than importing a generic reconstitution or stability period.
Follow the supplied label and product-specific documentation for storage conditions, temperature excursions and expiry. The time limits for dry peptide, a mixed solution, or a liquid-filled cartridge can differ. No generic fixed storage term, purity threshold or cold-chain guarantee is inserted here without applicable evidence. See peptide storage guidance and research-product receiving checklist for general laboratory-record practices.
At receipt, compare the product name, labelled amount and presentation with your order. Inspect the vial closure or cartridge/packaging, record the lot identifier and retain the accompanying paperwork. If damaged, delayed or different from the order, record photographs and contact Core Research before using the material. This records receipt conditions; it does not substitute for an identity assay.
Ordering questions
Does the labelled milligram amount state purity or a prepared concentration?
No. 10mg is the catalogue-labelled quantity for this item. It does not by itself establish analytical content, purity, final liquid concentration, sample mass basis or number of experiments. The applicable material documentation and your laboratory’s own method establish those details.
Where is the product dispatched from and what is the delivery policy?
Core Research states that it dispatches from Birmingham, United Kingdom, using plain external packaging. Delivery service, charge and arrival estimates depend on the destination and order; see Shipping & Delivery. Tracking is provided in dispatch communications where available. There is no universal next-day delivery or free-shipping promise on this page.
Can I obtain an applicable certificate before ordering?
You can request information before ordering through Batch Documentation. Specify SS-31 10mg, the vial presentation and any required test/method. Whether a particular current lot has a document, and what it actually reports, must be checked rather than assumed.
Can an institution request a quotation?
Yes. Institutional Procurement describes the written quotation and purchase-order-reference enquiry route. Include the institution, delivery details, exact product and quantity, and any lot or technical requirements. An enquiry does not itself reserve stock or guarantee credit terms.
Is this product suitable for human or veterinary use?
No. This listing is for in-vitro laboratory research only. Neither a positive model result nor a named medicinal compound establishes human-use suitability, and this page gives no preparation, dosing or administration instructions. See Research Use Only policy.
Order or enquire about SS-31 10mg
Use the native product purchase panel to select the listed quantity and the checkout options available for your order. For identity, format, lot-documentation or delivery questions, contact Core Research before purchase. Current price and stock remain controlled by WooCommerce, not hard-coded in this description.
Selected research references
[1] Birk AV et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. PMID 23813215. DOI 10.1681/ASN.2012121216. Primary research record.
[2] Mitochondrial protein interaction landscape of SS-31 (2020). Mass-spectrometry cross-linking study. PMID 32554501. Primary research record.
[3] Thompson WR et al. (2021). A phase 2/3 randomised clinical trial followed by an open-label extension of elamipretide in Barth syndrome. Genetics in Medicine. PMID 33077895. DOI 10.1038/s41436-020-01006-8. Primary research record.
[4] Long-term efficacy and safety of elamipretide in Barth syndrome: 168-week open-label extension of TAZPOWER (2024). Genetics in Medicine. PMID 38602181. Primary research record.




